Serious adverse events attributable to vitamin D supplementation were rare across all studies .
On the basis of studies review ed to date , the strongest evidence supports further research into adjunctive vitamin D therapy for tuberculosis , influenza , and viral upper respiratory tract illnesses .
OBJECTIVE To review the existing human controlled intervention studies of vitamin D as adjunctive therapy in setting s of infection and provide recommendations for design and implementation of future studies in this field on the basis of the evidence review ed .
Effect of Bimonthly Supplementation With Oral Cholecalciferol on Serum 25-Hydroxyvitamin D Concentrations in HIV-Infected Children and Adolescents
OBJECTIVE . Vitamin D insufficiency occurs commonly in HIV-infected youth in the United States . In light of the importance of vitamin D for skeletal and nonskeletal health , including innate immunity , developing methods for improving vitamin D status in HIV-infected children and adolescents is an important area of clinical research . The objective of this study was to evaluate the effect of administration of oral cholecalciferol , 100000 IU every 2 months , and 1 g/day calcium on serum 25-hydroxyvitamin D concentrations , serum and urine calcium , and HIV disease progression during a 12-month period . METHODS . HIV-infected children and adolescents who were aged 6 to 16 years were r and omly assigned to receive vitamin D ( 100000 IU bimonthly ) and calcium ( 1 g/day ; n = 29 ) or double placebo ( n = 27 ) . Serum 25-hydroxyvitamin D concentrations as measured by radioimmunoassay , albumin-corrected calcium concentrations , and spot urinary calcium-creatinine ratios were determined monthly . RESULTS . No abnormalities in serum calcium concentration were observed . One participant who received placebo  developed hypercalciuria . No group differences were seen in the change in CD4 count or CD4 % or viral load during 12 months . The overall mean monthly serum 25-hydroxyvitamin D concentrations were higher in the group that received vitamin D and calcium than in the placebo group , as was the monthly serum 25-hydroxyvitamin D area under the curve . After completing 12 months of study , 2 ( 6.7 % ) participants in the group that received vitamin D and calcium had a trough serum 25-hydroxyvitamin D concentration < 20 ng/mL compared with 14 ( 50 % ) in the placebo group . Twelve ( 44.4 % ) in the group that received vitamin D and calcium  had a trough serum 25-hydroxyvitamin D concentration of ≥30 ng/mL compared with 3 ( 11.1 % ) in the placebo group . CONCLUSIONS . Administration of oral cholecalciferol to HIV-infected children and adolescents at a dosage of 100000 IU every 2 months , together with 1 g/day calcium , is safe and results in significant increases in serum 25-hydroxyvitamin D concentrations
Serious adverse events attributable to vitamin D supplementation were rare across all studies .
On the basis of studies review ed to date , the strongest evidence supports further research into adjunctive vitamin D therapy for tuberculosis , influenza , and viral upper respiratory tract illnesses .
OBJECTIVE To review the existing human controlled intervention studies of vitamin D as adjunctive therapy in setting s of infection and provide recommendations for design and implementation of future studies in this field on the basis of the evidence review ed .